Skip to main content
Premium Trial:

Request an Annual Quote

NuGen Technologies, Source Precision Medicine, Girish Nallur, Symyx Technologies, V & P Scientific


NuGen Technologies of San Carlos, Calif., received US Patent 6,692,918, “Methods and compositions for linear isothermal amplification of polynucleotide sequences.” The patent covers methods for isothermal, single primer linear nucleic acid amplification using a composite primer, primer extension, strand displacement, and optionally a termination sequence.

Source Precision Medicine of Boulder, Colo., received US Patent No. 6,692,916, “Systems and methods for characterizing a biological condition or agent using precision gene expression profiles.” The patent covers methods for evaluating a biological condition of a subject using a calibrated profile data set derived from a data set containing a quantitative measure of the amount of a subject’s RNA or protein as distinct constituents in a panel of constituents. The biological condition may be a naturally occurring physiological state or may be responsive to treatment of the subject with one or more agents. Calibrated profile data sets may be used as a descriptive record for an agent.

Girish Nallur of Guilford, Conn., received US Patent No. 6,692,915, “Sequencing a polynucleotide on a generic chip.” The patent covers methods and devices for sequencing a polynucleotide by determining subsets of composite subsequences present in nucleic acid subsamples generated from the sample polynucleotide. A hairpin primer interrogates the composite subsequences in a two-step process resulting first in a polymerase-extended product whose synthesis identifies the first subsequence of the composite subsequence. The second subsequences are identified by hybridizing the polymerase extended products or amplified products to an array of capture probes where each capture probe is distinguishable from other capture probes. The invention is applicable to the quantitative determination of the presence of nucleic acids in a sample, for identification of differences in the relative abundance of nucleic acids in a mixture of nucleic acids, and generally, diagnostic aids for the identification of nucleic acids.

Symyx Technologies of Santa Clara, Calif., received US Patent No. 6,692,914, “Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto.” The patent covers sensors in the form of polymer brushes for determining the presence and concentration of biomolecules in a biological sample. The brushes comprise a substrate with a surface modified with a water-dispersible or water-soluble polymer segment having functional groups that bind probes. The method of synthesis of such sensors includes use of controlled free radical polymerization techniques, which allows for controlled architecture polymers to modify the surface of the substrate.

V & P Scientific of San Diego received US Patent No. 6,692,701, “Microarrayer.” The patent covers a device for providing incremental translation in multiple directions, having a base plate, a first plate, a second plate, and means for translation, such as differentially spaced holes. When the device includes an optional separate applicator with pins for delivering a specimen to a surface, such as a slide, the device can be used in a method for making microarrays.


The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.